- Home
- ALUR
as 04-02-2025 4:00pm EST
Stocks
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NATICK |
| Market Cap: | 19.1M | IPO Year: | N/A |
| Target Price: | $22.83 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $98.75 | Next Earning Date: | 03-26-2025 |
| Revenue: | $32,110,000 | Revenue Growth: | -39.94% |
| Revenue Growth (this year): | 2.18% | Revenue Growth (next year): | 35.85% |
Latest Allurion Technologies Inc. News
ALUR Breaking Stock News: Dive into ALUR Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Business Wire
13 days ago
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Business Wire
21 days ago
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
Business Wire
a month ago
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
Business Wire
a month ago
Allurion to Participate in Upcoming Investor Conferences
Business Wire
a month ago
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Business Wire
a month ago
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Business Wire
a month ago
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Compare ALUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALUR Allurion Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.